Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Trade Show

Meeting Demand for Biologics: The Bioprocessing Summit Explores Today's Challenges and Tomorrow's Advances


To meet exploding demand for biological drugs that can cure fatal diseases, counter chemical threats, or fight cancer, the bioprocessing industry is evolving to "digital biomanufacturing"? capitalizing on innovations like predictive analytics to fast track their protein-based therapies.

From August 12-16, 2019, more than 1,500 scientists, engineers and leaders from this international community will unite at The Bioprocessing Summit in Boston to explore the transformation ahead. They will also share new solutions to the challenges they encounter today, as they work to maximize quality, safety and cost-efficiency in the biologics manufacturing process.

"Distinguished by its high-caliber scientific content, the eleventh annual Bioprocessing Summit will offer abundant opportunities to access new data, case studies, technologies and techniques, and initiate valuable collaborations," said Mary Ruberry, Senior Conference Director, Cambridge Healthtech Institute, which produces this event.

This year's Plenary Keynote Sessions will focus on current challenges and future innovations:

Leading to Tomorrow's Advances (August 12)

Solving Today's Challenges (August 14)

The Bioprocessing Summit will include 200+ presentations on upstream and downstream processing, analytical and quality, formulation and stability, cell and gene therapy, manufacturing, and more.

In addition to one-on-one networking, an Exhibit Hall with 110+ cutting-edge innovators, and 80+ poster sessions, the conference will feature training seminars, special events sponsored by the International Society for Cell and Gene Therapy (ISCT), Women in Bio (WIB) and The National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), breakout discussions and short courses.

Please see bioprocessingsummit.com.

About Cambridge Healthtech Institute

Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Preclinical Congress, The Bioprocessing Summit, Next Generation Dx Summit, Immuno-Oncology Summit, and Discovery on Target. CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Bio-IT WorldClinical Research News and Diagnostics World.


These press releases may also interest you

at 15:02
The goal of humans again walking on the Moon is one giant leap closer. Lockheed Martin has completed building the capsule for NASA's Orion spacecraft. The crew module capsule for the uncrewed Artemis 1 mission to the Moon has been stacked on top of...

at 13:00
Accountnet Inc., a leading consulting firm and provider of cloud-based financial management solutions, announced that it has been named to Accounting Today's VAR 100 List for 2019. Accounting Today magazine is the leading provider of online business...

at 12:10
Compare-autoinsurance.org has launched a new blog post that explains more about car insurance agents and how they can help clients get the cheapest car insurance premiums. For more info and online car insurance quotes, visit...

at 11:10
Compare-autoinsurance.org has released a new article that presents the main reasons for using online car insurance quotes. For more info and free car insurance quotes, visit...

at 11:00
A small industrial park in central Connecticut is home to a fast-growing company that is literally shaping the future of construction. Network Framing Solutions (NFS) is a new manufacturer of prefabricated cold form steel using the state-of-the-art...

at 11:00
Marker Therapeutics, Inc. , a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced interim...



News published on 12 june 2019 at 10:25 and distributed by: